Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
26 Septembre 2024 - 8:30AM
Abivax to Present Three Abstracts for
Obefazimod in Ulcerative Colitis at the UEG Week 2024
- Professor Bruce E. Sands, MD to
present oral presentation of Phase 2b, open-label, maintenance
efficacy and safety data at weeks 48 and 96 among week 8 induction
non-responders in obefazimod-treated patients with moderately to
severely active ulcerative colitis (UC)
- Two moderated poster presentations
highlighting corticosteroid-free efficacy and safety data of
obefazimod at weeks 48 and 96 of an open-label maintenance trial,
as well as the impact of obefazimod induction therapy on combined
histologic and endoscopic outcomes at week 8 in patients with
UC
PARIS, France, September 26, 2024 –
08:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284
– ABVX; NASDAQ: ABVX) (“Abivax” or the “Company”), a clinical-stage
biotechnology company focused on developing therapeutics that
harness the body’s natural regulatory mechanisms to stabilize the
immune response in patients with chronic inflammatory diseases,
today announced that three scientific abstracts on its lead drug
candidate, obefazimod, will be presented during the United European
Gastroenterology (UEG) Week meeting, Oct. 12-15, 2024, in
Vienna, Austria.
“We look forward to returning to UEGW to share
new analysis of our Phase 2b trial data on obefazimod in patients
with moderately to severely active ulcerative colitis,” said
Abivax Chief Medical Officer Fabio Cataldi, MD.
“With this presentation, we have observed additional evidence that
obefazimod has the potential to advance the treatment paradigm,
designed to be a once-daily oral therapy, for people living with
ulcerative colitis.”
For more information on the Abivax clinical
program and company updates, please see the conference program at
the UEG website.
Obefazimod data to be
presented:
Presentation Title |
Session |
Presenter |
Abstract/Poster Number |
Date/Time of Presentation |
Oral Presentation |
Efficacy and safety of obefazimod in UC patients at week 48 of an
open-label maintenance study among clinical non-responders at week
8 of the Phase 2b induction trial |
IBD New horizons in medical treatment - Part 2 |
Prof. Bruce E. Sands, M.D., M.S.Dr. Burrill B. Crohn Professor of
Medicine and Chief, Dr. Henry D. Janowitz Division of
Gastroenterology, Icahn School of Medicine at Mount Sinai, NY |
|
Tuesday, Oct. 15, 2024, from 11:30 AM to 12:30 PM CEST |
Moderated Poster Presentations |
Corticosteroid-free efficacy and safety of UC patients receiving
once-daily obefazimod in an open label 96-week maintenance study
among patients who were receiving concomitant corticosteroids at
induction baseline |
Small molecules in the treatment of IBD |
Prof. Séverine Vermeire, MD, PhD.Head of the IBD Center at the
University Hospitals Leuven, Belgium, and principal investigator in
Europe for the study programs conducted and ongoing with obefazimod
in UC |
|
Tuesday, Oct. 15, 2024, from 14:30 PM to 15:30 PM CEST |
Impact of obefazimod induction therapy on histologic and combined
histologic and endoscopic outcomes in patients with moderately to
severely active ulcerative colitis: week 8 results from the Phase
2b inductiontrial |
Small molecules in the treatment of IBD |
Prof. Britta Siegmund, MD, PhDMedical Director, Division of
Gastroenterology, Infectiology and Rheumatology,
Universitätsmedizin Berlin |
|
Tuesday, Oct. 15, 2024, from 14:30 PM to 15:30 PM CEST |
*****
About Obefazimod
Obefazimod, Abivax’s lead investigational drug
candidate, is an orally administered small molecule that was
demonstrated to potentially enhance the expression of a single
microRNA, miR-124. Phase 2 clinical trials in patients with UC have
generated positive data, resulting in the initiation of a pivotal
global Phase 3 clinical trial program (ABTECT Program), with first
patients enrolled in the United States in October 2022. Initiation
of a Phase 2b clinical trial in Crohn’s disease is expected in Q3
2024, and exploration of potential combination therapy
opportunities in UC is ongoing.
About Abivax Abivax is a
clinical-stage biotechnology company focused on developing
therapeutics that harness the body’s natural regulatory mechanisms
to stabilize the immune response in patients with chronic
inflammatory diseases. Based in France and the United States,
Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3
clinical trials for the treatment of moderately to severely active
ulcerative colitis. More information on the Company is available at
www.abivax.com. Follow us on LinkedIn and X, formerly Twitter,
@ABIVAX.
Contact:Patrick MalloySVP,
Investor Relations Abivax SApatrick.malloy@abivax.com+1 847 987
4878
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements, forecasts and estimates, including those relating to
the Company’s business and financial objectives. Words such as
“expect,” “forward”,” will” and variations of such words and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements include
statements concerning or implying the therapeutic potential of
Abivax's drug candidates, as well as the timing of initiation of a
Phase 2b clinical trial of obefazimod in Crohn’s disease. Although
Abivax’s management believes that the expectations reflected in
such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are
subject to various risks, contingencies and uncertainties,
many of which are difficult to predict and generally beyond the
control of Abivax, that could cause actual results and developments
to differ materially from those expressed in, or implied or
projected by, the forward-looking information and
statements. A description of these risks, contingencies and
uncertainties can be found in the documents filed by the Company
with the French Autorité des Marchés Financiers pursuant to its
legal obligations including its universal registration document
(Document d’Enregistrement Universel) and in our Annual Report on
Form 20-F filed with the U.S. Securities and Exchange Commission on
April 5, 2024 under the caption “Risk Factors.” These risks,
contingencies and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical
data and analysis, decisions by regulatory authorities, such as the
FDA or the EMA, regarding whether and when to approve any drug
candidate, as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates. Special consideration should be given
to the potential hurdles of clinical and pharmaceutical development
including further assessment by the company and regulatory agencies
and IRBs/ethics committees following the assessment of preclinical,
pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data.
Furthermore, these forward-looking statements, forecasts and
estimates are only as of the date of this press release. Readers
are cautioned not to place undue reliance on these forward-looking
statements. Abivax disclaims any obligation to update these
forward-looking statements, forecasts or estimates to reflect any
subsequent changes that the Company becomes aware of, except as
required by law. Information about pharmaceutical products
(including products currently in development) which is included in
this press release is not intended to constitute an
advertisement. This press release is for information purposes
only, and the information contained herein does not constitute
either an offer to sell, or the solicitation of an offer to
purchase or subscribe securities of the Company in any
jurisdiction. Similarly, it does not give and should not be treated
as giving investment advice. It has no connection with the
investment objectives, financial situation or specific needs of any
recipient. It should not be regarded by recipients as a substitute
for exercise of their own judgment. All opinions expressed herein
are subject to change without notice. The distribution of this
document may be restricted by law in certain jurisdictions. Persons
into whose possession this document comes are required to inform
themselves about and to observe any such restrictions.
Abivax (EU:ABVX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Abivax (EU:ABVX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024